{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:51:15Z","timestamp":1792702275729,"version":"4.5.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Diabetic ketoacidosis is rarely observed when the blood glucose level is &lt;250\u2009mg\/dL. This is referred to as euglycemic diabetic ketoacidosis (EDKA). EDKA can present diagnostic and management challenges for physicians, especially when dealing with unusual triggers such as glucagon-like peptide 1 (GLP1) receptor agonists and sodium-glucose co-transporter 2 inhibitors. With this case report, we wanted to raise the knowledge and understanding of EDKA and its triggering factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 45-year-old man was admitted to hospital for epigastric pain, loss of appetite, and vomiting 3 days after the initiation of dulaglutide. The results of laboratory examination showed EDKA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient was diagnosed with EDKA after the initiation of GLP1 receptor agonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Intravenous fluid and insulin infusion were immediately started.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome:<\/jats:title>\n                    <jats:p>The patient was discharged after treatment<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>In this case report describes the use of GLP1 receptor agonists along with Sodium-glucose co-transporter 2 inhibitors in type 2 diabetes patients whose extreme restriction of carbohydrate intake may have triggered EDKA. Therefore, physicians should use diabetes medications in a stepwise manner and advise their patients not to over-restrict their carbohydrate intake while they are being treated with GLP1 receptor agonists.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000034027","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T10:07:29Z","timestamp":1686305249000},"page":"e34027","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9838-0376","authenticated-orcid":false,"given":"Rabia Khalid","family":"Alduraibi","sequence":"first","affiliation":[{"name":"Department of Endocrine and Diabetes, King Fahad Specialist Hospital, Buraydah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed Mohammed","family":"Alrebdi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Fahad Specialist Hospital, Buraydah, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef Fahad","family":"Altowayan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Fahad Specialist Hospital, Buraydah, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes.","volume":"32","author":"Kitabchi","year":"2009","journal-title":"Diabetes Care"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11606-008-0829-0","article-title":"Starvation-induced true diabetic euglycemic ketoacidosis in severe depression.","volume":"24","author":"Joseph","year":"2009","journal-title":"J Gen Intern Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/sj.jp.7211921","article-title":"Normoglycemic diabetic ketoacidosis in pregnancy.","volume":"28","author":"Chico","year":"2008","journal-title":"J Perinatol"},{"key":"R5-20250504","first-page":"17","article-title":"Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma.","volume":"2017","author":"Rawla","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors.","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor\u2013associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis.","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin Ther"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/bmj.2.5866.578","article-title":"Euglycaemic diabetic ketoacidosis.","volume":"2","author":"Munro","year":"1973","journal-title":"Br Med J"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF00569937","article-title":"Euglycaemic diabetic ketoacidosis: does it exist?","volume":"30","author":"Jenkins","year":"1993","journal-title":"Acta Diabetol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s13300-019-00680-5","article-title":"Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes.","volume":"10","author":"Nagahisa","year":"2019","journal-title":"Diabetes Ther"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.numecd.2021.10.003","article-title":"The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system.","volume":"32","author":"Yang","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"},{"issue":"Supplement_1","key":"R13-20250504","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20132021.","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials.","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00592-011-0340-7","article-title":"The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.","volume":"50","author":"Raschi","year":"2013","journal-title":"Acta Diabetol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e000475","DOI":"10.1136\/bmjdrc-2017-000475","article-title":"Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA adverse event reporting system.","volume":"6","author":"Fadini","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"bcr2017220437","DOI":"10.1136\/bcr-2017-220437","article-title":"Is it safe to acutely discontinue insulin therapy in patients with chronic hyperglycaemia starting GLP-1R agonists?","volume":"2017","author":"Okiro","year":"2017","journal-title":"BMJ Case Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T22:06:07Z","timestamp":1746309967000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":16,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034027","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}